Skip to main content
. Author manuscript; available in PMC: 2014 Feb 19.
Published in final edited form as: Future Lipidol. 2008 Aug 1;3(4):453–467. doi: 10.2217/17460875.3.4.453

Figure 5.

Figure 5

Endocannabinoids (eCBs) in prostate cancer. (A) Structures of some of well-characterized endocannabinoids (shown are AA-derived eCBs), anandamide (AEA), 2-arachidonoylglycerol (2-AG), and noladin ether (NE). (B) Mechanistic pathways for eCBs. Hydrolysis of eCBs produces free AA which is further metabolized by oxygenases to eicosanoids in the AA pathways. The eCBs bind to cannabinoid receptor type 1 (CB1 receptor) to inhibit prostate caner cell proliferation and invasion/migration; however, the role of CB2 receptor is not clear. The eCBs can inhibit prostate cancer proliferation by a non-receptor-mediated pathway.